C9orf72 and amyotrophic lateral sclerosis: The DPR knockdown efficiency ranged from approximately 20% to 90% among the different lines (Figure 3G), confirming the effectiveness of the CRISPR/Cas13d system in motor neurons derived from C9orf72 repeat–associated ALS patients.